Thus, to optimize the uveal melanoma therapy and obtain greater efficacy in the future, studies could be conducted with darovasertib, in combination with other drugs that inhibit other tyrosine kinases, such as VEGF-B and PD-1/CTLA-4 inhibitors. This evidence concerns the gene VEGFB and uveal melanoma.